Welcome to our dedicated page for Charlie S Holdin news (Ticker: CHUC), a resource for investors and traders seeking the latest updates and insights on Charlie S Holdin stock.
Charlie’s Holdings, Inc. reports developments in premium vapor products and electronic nicotine delivery systems. The company sells product lines including SBX, Pachamama and PACHA through distributors, specialty retailers and online resellers, with operating activity tied to Charlie’s Chalk Dust, LLC.
Recurring updates center on FDA Premarket Tobacco Product Applications, state vapor-product requirements, age-verification technology for device activation, product-line distribution, trade-show participation, financial results and capital actions such as private placements and debt forgiveness.
Charlie's Holdings, Inc. (OTCQB:CHUC) reported significant financial growth for 2021, with a 29% revenue increase to $21.5 million and a net income of $4.8 million, up from a net loss of $7.2 million the previous year. Key highlights include a 53% revenue growth in Q4, operating expenses down 34%, and successful PMTA submissions still viable with the FDA. The company aims to expand into hemp-derived products and international markets while strengthening its PMTA strategy, led by new Board member, PMTA expert Edward Carmines.
Charlie's Holdings (OTCQB: CHUC) appointed Dr. Edward Carmines to its Board of Directors. Carmines, a regulatory expert, has experience with the FDA, including successful PMTA and MRTPA applications. This appointment is timely, as the FDA has issued numerous marketing denial orders affecting e-cigarette products. The leadership hopes Carmines' expertise will enhance the Company's existing PMTAs currently under review. His previous successes include being the architect behind a notable MRTP marketing order at 22nd Century Group.
Charlie's Holdings, Inc. (OTCQB:CHUC) reported its Q3 2021 financial results, showcasing a 34% increase in revenue to $5.2 million compared to Q3 2020. The company's gross profit rose 31% to $2.9 million, while operating income improved significantly to $0.4 million, reversing a loss of $0.9 million last year. Net income surged to $3.1 million, up from a loss of $6.8 million, aided by a gain in fair value of derivative liabilities. Management highlighted ongoing progress towards uplisting and confidence in PMTA submissions.
Charlie's Holdings, Inc. (OTCQB:CHUC) is transitioning to a board with a majority of independent directors, as announced on November 3, 2021. CEO Brandon Stump has resigned to facilitate this transition, while remaining the largest shareholder after investing an additional $3 million. Inside directors Keith Stump and David Allen are also resigning. The company aims to uplist to a national securities exchange and plans to appoint new independent directors by January 1, 2022. The executive management team, led by COO Ryan Stump and President Henry Sicignano, is recognized for their expertise and is expected to drive future growth.
Charlie's Holdings, Inc. (OTCQB:CHUC) announced that its Premarket Tobacco Product Applications (PMTAs) for its top-selling e-liquids have passed the FDA's filing review and entered the Substantive Review phase. This positions the company favorably compared to competitors, as over 992,000 flavored e-cigarette products received Marketing Denial Orders, while Charlie's submissions include over $5 million in scientific data and studies aimed at proving public health benefits. The company anticipates a competitive advantage leading to increased sales and market share.
Charlie's Holdings, Inc. (OTCQB: CHUC) reported a 31% revenue increase to $5.4 million for Q2 2021, alongside an operating loss reduction of 78% to $168,000. The gross profit rose 9% to $2.6 million. Key advancements included the FDA's PMTA submission for top-selling e-liquids and the launch of Pachamama Disposables. The company aims for profitability, supported by a solid balance sheet and strong market momentum.
Charlie's Holdings, Inc. (OTCQB:CHUC) announced its uplisting from the OTC Pink Market to the more prestigious OTCQB Venture Market, effective August 3, 2021. This shift enhances the company's visibility and credibility in capital markets. Charlie's aims to appeal to a broader investor base and move closer to uplisting on a national exchange. The company is also navigating the FDA's Premarket Tobacco Application process and has projected revenue growth for 2021. Improved financials and compliance with OTCQB standards signify a positive trajectory for the company.
Charlie's Holdings, Inc. (OTC Pink:CHUC) announced a 1-for-100 reverse stock split effective June 16, 2021, with necessary approvals from FINRA. The share count will reduce from approximately 20.3 billion to 203.2 million, enhancing capital markets appeal and supporting a future uplisting to a national exchange. The split aims to attract a broader investor base, and following the split, shares will temporarily trade as CHUCD for 20 days. The company anticipates growth in revenue for FY 2021 compared to 2020, supported by recent stock purchases totaling $3 million by executives.
Charlie's Holdings, Inc. (OTC PINK:CHUC) announced its best-selling e-liquids have received inclusion on the FDA's list of deemed new tobacco products, following timely submission of a Premarket Tobacco Product Application (PMTA). This marks a significant milestone as Charlie's is one of the few companies to pass the FDA's filing phase and enter the Substantive Review phase. Charlie's commitment to regulatory compliance is expected to provide a competitive edge, potentially boosting sales, profits, and market share, while other firms face product withdrawals.
Charlie's Holdings, Inc. (OTC PINK:CHUC) reported significant improvements for Q1 2021, with revenue rising 3% to $4,361,000 from Q4 2020, despite a 1% year-over-year decline. Gross profit increased more than 14% to $2,418,000, with gross margin expanding to 55%. Operating loss decreased by 95% to $229,000. The company closed a $3 million capital raise and introduced the new Pachamama Disposables™ line. Charlie's PMTA is under substantive review with the FDA, providing a potential competitive edge in the premium e-liquid market.